


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Compounds~~ A compound of the general formula
(I): (I)



(I)

~~in which:~~ wherein

X = ~~O~~ or is S;

R1 is ~~chosen from:~~

- Alk-COOH,
- Alk-C(=O)-(O)_m-Ar,
- Alk-C(=O)-(O)_m-Het,
- Alk-C(=O)-(O)_m-Alk,
- Alk-C(=O)-(O)_m-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-(O)_m-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar, or
- Alk-O-Het;

R2 is ~~chosen from~~ -OH, -OAlk, -NR₇R₈, -OAr, -OHet and or -O-cycloalkyl;

R7 is ~~chosen from~~ H and or -Alk;

R8 is ~~chosen from~~

- H;
- Alk' or -cycloalkyl,

~~in which~~ Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~
of -OAlk, -CN, -OHet, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-

(O)_m-cycloalkyl, -COOH and or -NO₂;

-Ar' or Het',

in which Ar' or Het' is optionally substituted by one or more groups ~~chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH -NRR', -Het, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_m-cycloalkyl and or NO₂;

or R7 and R8 form, together with the nitrogen atom to which they are attached, a nitrogenous heterocycle of 5 to 10 atoms;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and or -NO₂;

~~in which, in the definitions of R1-R8:~~

~~each of the Alk,~~ each of which may be identical or different, is optionally and independently substituted by one or more groups ~~chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and or -NO₂;

~~each of the Ar,~~ each of which may be identical or different, is optionally and independently substituted by one or more groups ~~chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -Het, -NO₂, -S(O)_n-Ar and or -S(O)_nAlk;

R and R' are, each ~~chosen~~ independently, from H and or Alk;

m = ~~0~~ is 0 or 1;

n = ~~0~~ is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical;

Het and Het' are, each independently, a heteroaryl radical; and

Hal is a halogen radical;

~~and also the stereoisomers thereof, and the racemates and~~ or a pharmaceutically acceptable salts salt thereof,

with the exception of the compounds for which :

- 1) R1 = CH₂-phenyl, optionally substituted by -NO₂ or -OMe,
R2 = -OMe, -OEt or -OH,
R3, and R6 = H,

R4, and R5 = H or -OMe, and

X = O ~~or~~ S₂ ~~or~~

- 2) R1 = -CH₂-C(=O)Me,
R3, R4, R5, and R6 = H, X = O ~~and~~ R2 = -OEt ~~or~~
X = S₂ and
R2 = -OMe;

- 3) ~~R1 = -CH₂-CO₂Et, R2 = -OEt, R3, R4, R6 = H, X = O and R5 = -NH₂ or -NO₂; or~~

R1 = -CH₂-CO₂Me,
R3, R4, R5, and R6 = H,
R2 = -OMe or -OH₂ ~~and~~ X = O ~~or~~ S₂ ~~or~~ R2 = -OH and
X = S₂ ~~or~~

and

R1 = -CH₂CO₂H,
R3, R4, R5, and R6 = H,
R2 = OH₂ and
X = S₂;

and

- 4) R1 = -CH₂-phenyl,
R2 = -NH₂,
X = O, S₂ and
R5 = -OMe, ~~or~~ X = O ~~and~~ R5 = phenyl.

2. (Currently Amended) Compounds A ~~compound of the general formula (I)~~
according to Claim 1, ~~in which:~~ wherein

~~R2 =~~ R2 is -Oet; ~~and~~ X = S₂ and

R1 is ~~chosen from:~~

-Alk-COOH,

-Alk-C(=O)-(O)_m-Ar,

-Alk-C(=O)-(O)_m-Het,
 -Alk-C(=O)-(O)_m-Alk,
 -Alk-C(=O)-(O)_m-cycloalkyl,
 -Alk-C(=O)NRR',
 -Alk-(O)_m-Ar,
 -Alk-O-Alk,
 -Alk-O-Alk-Ar, or
 -Alk-O-Het; [[;]]

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and or -NO₂;
~~in which, in the definitions of R1-R8:~~

~~each of the Alk, each of~~ which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from of~~ -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and or -NO₂;

~~in which each of the Ar, each~~ which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from of~~ -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -Het, -NO₂, -S(O)_n-Ar and or -S(O)_nAlk;

R and R' are, each ~~chosen~~ independently, from H and or Alk;

~~m=~~ m is 0 or 1;

~~n=~~ n is 0, 1 or 2 [[;]]

~~and also the stereoisomers thereof, and the racemates and pharmaceutically acceptable salts thereof.~~

3. (Currently Amended) ~~Compounds of the general formula (I)~~ A compound according to Claim 1, in ~~which:~~ which

~~X=O or S;~~

R1 is ~~chosen from:~~

-Alk-COOH,
 -Alk-C(=O)-(O)_m-Ar,
 -Alk-C(=O)-(O)_m-Het,
 -Alk-C(=O)-(O)_m-Alk,

-Alk-C(=O)-(O)_m-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-(O)_m-Ar,

-Alk-O-Alk,

-Alk-O-Alk-Ar, or

-Alk-O-Het;

~~R2=~~ R2 is -NR⁷R⁸ in which

R⁷ is ~~chosen from~~ H and or -Alk;

R⁸ is ~~chosen from~~

-Alk' or -cycloalkyl,

~~in which~~ Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_mcycloalkyl, -COOH and or -NO₂;

-Ar' or Het';

~~in which~~ Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -NRR', -Het, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_mcycloalkyl and or NO₂;

R³, R⁴, R⁵ and R⁶, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and or -NO₂;

~~in which each of the~~ Alk, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and or -NO₂;

~~in which each of the~~ Ar, each of which may be identical or different, is optionally and independently substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -Het, -NO₂, -S(O)_n-Ar and or -S(O)_nAlk;

R and R' are, each ~~chosen~~ independently, ~~from~~ H and or Alk;

~~m=~~ m is 0 or 1;

~~n=~~ n is 0, 1 or 2;

~~X=O or is~~ S;

~~R1 is chosen from:~~

~~-Alk-COOH,~~

~~-Alk-C(=O)-(O)_m-Ar,~~

~~-Alk-C(=O)-(O)_m-Het,~~

~~-Alk-C(=O)-(O)_m-Alk,~~

~~-Alk-C(=O)-(O)_m-cycloalkyl,~~

~~-Alk-C(=O)NRR',~~

~~-Alk-(O)_m-Ar,~~

~~-Alk-O-Alk,~~

~~-Alk-O-Alk-Ar,~~

~~-Alk-O-Het,~~

~~and also the stereoisomers thereof, and the racemates and pharmaceutically acceptable salts thereof,~~

4. (Currently Amended) Compounds A compound of the formula (I) according to Claim 1, in which R3, R4, R5, and R6 = H are H.

5. (Cancelled)

6. (Currently Amended) Compounds A compound of the formula (I) according to Claim 1, in which ~~R2=~~ R2 is -OAlk.

7. (Currently Amended) Compounds A compound of the formula (I) according to Claim 1, in which ~~m=~~ m is 0.

8. (Currently Amended) Compounds A compound of the formula (I) according to Claim 1, in which ~~R2=~~ R2 is -NR7R8,

~~in which~~

~~R7=~~ R7 is H or Alk, and

~~R8=~~ R8 is -Alk' optionally substituted by -C(=O)-OAlk, -Het' or, -Ar' optionally substituted by -Hal, -C(=O)OAlk or -Alk-C(=O)OAlk.

9. (Currently Amended) Compounds A compound of the formula (I)

according to Claim 1, in ~~which~~: which

~~R1=~~ R1 is -CH₂-COOH, -CH₂-C(=O)-(O)_m-Ar, -CH₂-C(=O)-(O)_m-Het, -CH₂-C(=O)-(O)_m-Alk, -CH₂-C(=O)NRR', -CH₂-(O)_m-Ar, -CH₂-O-Alk, -CH₂-O-Alk-Ar, or -CH₂-O-Het;
~~in which~~

Ar is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -Ar, -Alk, -O-Alk-Ar, -C(=O)-(O)_m-Alk, -Alk-C(=O)-(O)_mAlk, -S(O)_n-Ar, -S(O)_n-Alk, -O-CF₃, -CN and or -OH,

~~in which m=~~ m is 0 or 1, and ~~n=~~ n is 2.

10. (Currently Amended) ~~Compounds A compound of the formula (I)~~
according to Claim 1, in which ~~R1=~~ R1 is -CH₂-C(=O)-Ar, -CH₂-C(=O)-Alk or -(CH₂)_m'-
(O)_m-Ar, ~~in which~~

Ar is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -Ar, -Alk, -O-Alk-Ar, -C(=O)-(O)_m-Alk, -Alk-C(=O)-(O)_mAlk, -S(O)_n-Ar, -S(O)_n-Alk, -O-CF₃, -CN and or -OH,

~~in which m=~~ m is 0 or 1, ~~m'=~~ m' is 1 or 2, and ~~n=~~ n is 2.

11. (Currently Amended) ~~Compounds A compound of the formula (I)~~
according to Claim 10, in which ~~m'=~~ m' is 2 if and ~~m=~~ m is 1.

12. (Currently Amended) ~~Compounds A compound of the formula (I)~~
according to Claim 1, in which ~~Ar=~~ Ar is phenyl.

13. (Currently Amended) ~~Compounds A compound of the formula (I)~~
according to Claim 1, in which ~~R1=~~ R1 is -CH₂-C(=O) Alk.

14. (Currently Amended) ~~Compounds A compound of the formula (I)~~
according to Claim 13, in which ~~Alk=~~ Alk is -CMe₃.

15. (Currently Amended) ~~Compounds A compound of the formula (I)~~
according to Claim 1, in which ~~R1=~~ R1 is -CH₂-C(=O)-phenyl or -CH₂-phenyl, in which
phenyl is optionally substituted by one or more ~~groups chosen from~~ of -Hal, -OAlk and or


-CN.

16. (Currently Amended) ~~Compounds~~ A compound according to Claim 1,
~~chosen from:~~ which is

ethyl 3-[2-(4-chlorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(2-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-biphenyl-4-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-oxo-2-*p*-tolylethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-adamantan-1-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(4-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(4-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(1-methyl-2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(2,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(3,3-dimethyl-2-oxobutoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-naphthalen-2-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(2,3-dichloro-4-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(2-benzyloxy-5-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-hydroxybenzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(4-fluorophenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-phenethyloxybenzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-phenoxyethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(4-cyanophenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-{2-[4-(2-methoxycarbonylethyl)phenoxy]ethoxy}benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(naphthalen-1-yloxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(2-methoxyphenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-[2-(2,3-dimethylphenoxy)ethoxy]benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2'-cyanobiphenyl-4-ylmethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-hydroxy-3-phenoxypropoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(3-phenoxypropoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-cyanobenzyloxy)benzo[*b*]thiophene-2-carboxylate;

ethyl 3-(3-cyanobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-cyanobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(2-benzenesulfonylmethylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-methoxycarbonylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-trifluoromethoxybenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-pentafluorophenylmethoxybenzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(naphthalen-2-ylmethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(3-methoxybenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-fluorobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-bromobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-(4-methylbenzyloxy)benzo[*b*]thiophene-2-carboxylate;
ethyl 3-benzyloxybenzo[*b*]thiophene-2-carboxylate; or
ethyl 3-(2,3-difluorobenzyloxy)benzo[*b*]thiophene-2-carboxylate;
~~and also the stereoisomeric forms, and the racemates and~~ or a pharmaceutically acceptable
salts salt thereof.

17. (Currently Amended) ~~Process A process for the preparation preparing~~
of a compound ~~of the formula (I)~~ according to Claim 1, comprising ~~the step consisting in~~
using: reacting
a compound of the formula (IV)




with a halo-derivative of the compound of formula (V): (V)

Hal-R1 (V)

~~in which wherein~~ R1-R6 and X are defined as in ~~any one of the preceding claims, with an~~
equimolar amount; for the compounds of formula (I), in a polar solvent, at a temperature of


from -20 to 200°C.

18. (Currently Amended) ~~Process for the preparation of the compounds of the formula (I), for which the compound of the formula (IV) is obtained by adding~~ A process for preparing a compound according to claim 1, comprising reacting a compound of the formula (II): (II)



(II)

~~in which wherein R3-R6 and X are as defined in Claim 1 for the compounds of formula (I), and R represents a hydrogen atom or an alkyl radical, to with a 2-haloethanone derivative of the compound of formula (III): (III)~~




(III)

~~in which wherein Hal represents a halogen atom and R2 is as defined in any one of Claims 1 to 16 for the compounds of formula (I), in a polar solvent, at a temperature of from -20 to 200°C, followed by cyclization in a polar solvent, at a temperature of from -20 to 200°C.~~

19. (Currently Amended) ~~Process for the preparation of the compounds of the formula (I)~~ A process according to Claim 17, for which the said wherein the polar solvent is chosen from: ethanol, methanol, water, DMF, NMP, DMSO and or iPrOH.

20. (Currently Amended) ~~Pharmaceutical compositions~~ A pharmaceutical composition comprising the compounds of the a pharmaceutically acceptable carrier and a compound of formula (I): (I)



(I)

in which: which

X = ~~O~~ or is S;

R1 is ~~chosen from~~:

-Alk-COOH,

-Alk-C(=O)-(O)_m-Ar,

-Alk-C(=O)-(O)_m-Het,

-Alk-C(=O)-(O)_m-Alk,

-Alk-C(=O)-(O)_m-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-(O)_m-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar, or

-Alk-O-Het;

R2 is ~~chosen from~~ -OH, -OAlk, -NR₇R₈, -OAr, -OHet and or -O-cycloalkyl;

R7 is ~~chosen from~~ H and or -Alk;

R8 is ~~chosen from~~

-H;

-Alk' or -cycloalkyl,

in which Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_m-cycloalkyl, -COOH and or -NO₂;

-Ar' or Het',

in which Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH -NRR', -Het, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_m-cycloalkyl and or NO₂;

or R7 and R8 form, together with the nitrogen atom to which they are attached, a nitrogenous heterocycle of 5 to 10 atoms;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, ~~from~~ H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and or -NO₂;

~~in which, in the definitions of R1-R8:~~

~~each of the Alk, each of which may be identical or different, is optionally and independently substituted by one or more groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and or -NO₂;

~~each of the Ar, each of which may be identical or different, is optionally and independently substituted by one or more groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -Het, -NO₂, -S(O)_n-Ar and or -S(O)_nAlk;

R and R' are, ~~chosen~~ independently, ~~from~~ H and or Alk;

~~m=~~ m is 0 or 1;

~~n=~~ n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical;


Het and Het' are, each independently, a heteroaryl radical; and

Hal is a halogen radical;

~~and also the stereoisomers thereof, and the racemates and~~ or a pharmaceutically acceptable salts salt thereof.

21. (Currently Amended) ~~Pharmaceutical compositions, A pharmaceutical composition, in which X and R1-R6 are as defined according to comprising a pharmaceutically acceptable carrier and a compound of claim 2.~~

22. (Currently Amended) ~~Use of the compounds of the A method for reducing hyperglycaemia, comprising administering to a subject in need thereof an effective amount of a compound of formula (I): (I)~~



(I)

~~in which:~~ wherein

~~X = O or~~ is S;

~~R1 is chosen from:~~

-Alk-COOH,

-Alk-C(=O)-(O)_m-Ar,

-Alk-C(=O)-(O)_m-Het,

-Alk-C(=O)-(O)_m-Alk,

-Alk-C(=O)-(O)_m-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-(O)_m-Ar,

-Alk-O-Alk,

-Alk-O-Alk-Ar, or

-Alk-O-Het;

~~R2 is chosen from~~ -OH, -OAlk, -NR₇R₈, -OAr, -OHet and or -O-cycloalkyl;

~~R7 is chosen from~~ H and or -Alk;

~~R8 is chosen from~~

-H;

-Alk' or -cycloalkyl,

~~in which~~ Alk' or cycloalkyl is optionally substituted by one or more ~~groups chosen from~~ of -OAlk, -CN, -OHet, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_m-cycloalkyl, -COOH and or -NO₂;

-Ar' or Het',

~~in which~~ Ar' or Het' is optionally substituted by one or more ~~groups chosen from~~ of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH -NRR', -Het, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_mHet, -C(=O)-(O)_m-cycloalkyl and or NO₂;

or R7 and R8 form, together with the nitrogen atom to which they are attached, a

nitrogenous heterocycle of 5 to 10 atoms;

R3, R4, R5 and R6, which may be identical or different, are ~~chosen~~ each independently, from H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' and or -NO₂;

~~in which, in the definitions of R1-R8:~~

~~each of the Alk, each of which may be identical or different, is optionally and independently substituted by one or more groups chosen from~~ of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, -Het and or -NO₂;

~~each of the Ar, each of which may be identical or different, is optionally and independently substituted by one or more groups chosen from~~ of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -Het, -NO₂, -S(O)_n-Ar and or -S(O)_nAlk;

R and R' are, ~~chosen~~ each independently, from H and or Alk;

~~m=~~ m is 0 or 1;

~~n=~~ n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical;

Het and Het' are, each independently, a heteroaryl radical; and

Hal is a halogen radical;

~~and also the stereoisomers thereof, and the racemates and~~ or a pharmaceutically acceptable salts salt thereof;

~~for the manufacture of a medicament for reducing hyperglycaemia.~~

23. (Currently Amended) Use A method according to Claim 22, ~~for which the said medicament is for the treatment of~~ wherein diabetes is treated.

24. (Currently Amended) ~~Utilisation~~ A method according to Claim 22, ~~for which the said medicament is for the treatment of~~ wherein non-insulin-dependent diabetes is treated.

25. (Currently Amended) Use A method according to Claim 22, ~~for which~~

~~the said medicament is for the treatment of~~ wherein dyslipidaemia and/or obesity is treated.

26. (Currently Amended) Use A method according to Claim 22, ~~for which~~
~~the said medicament is for the treatment of and/or preventing~~ wherein a diabetes-related
microvascular ~~and or~~ macrovascular ~~complications~~ complication is treated or prevented.

27. (Currently Amended) Use A method according to Claim 26, ~~for which~~
~~the said~~ wherein the microvascular ~~and or~~ macrovascular ~~complications are chosen from~~
complication is atherosclerosis, arterial hypertension, ~~a~~ diabetes-related inflammatory
~~processes process~~, microangiopathy, macroangiopathy, retinopathy ~~and or~~ neuropathy.

28. (Cancelled)

29. (New) A pharmaceutical composition, comprising a pharmaceutically
acceptable carrier and a compound of claim 1.

30. (New) A method for reducing hyperglycaemia, comprising
administering to a subject in need thereof an effective amount of a compound of claim 1.

31. (New) A compound of claim 1, wherein

R1 is

-Alk-COOH,

-Alk-C(=O)-(O)_m-Ar,

-Alk-C(=O)-(O)_m-Alk,

-Alk-C(=O)-(O)_m-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-(O)_m-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar;

R2 is -OH, -OAlk, -NR⁷R⁸, -OAr, or -O-cycloalkyl;

R⁷ is H or -Alk;

R8 is

-H;

-Alk' or -cycloalkyl,

which Alk' or cycloalkyl is optionally substituted by one or more of -OAlk, -CN, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_m-cycloalkyl, -COOH or -NO₂;

-Ar',

which Ar' is optionally substituted by one or more of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH -NRR', -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_m-cycloalkyl or NO₂;

R3, R4, R5 and R6, which may be identical or different, are each independently, H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' or -NO₂;

Alk, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, or -NO₂;

Ar, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -NO₂, -S(O)_n-Ar or -S(O)_nAlk;

R and R' are, each independently, H or Alk;

m is 0 or 1;

n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical; and

Hal is a halogen radical;

or a pharmaceutically acceptable salt thereof.

32. (New) A pharmaceutical composition of claim 20, wherein

X is S;

R1 is

-Alk-COOH,

-Alk-C(=O)-(O)_m-Ar,
 -Alk-C(=O)-(O)_m-Alk,
 -Alk-C(=O)-(O)_m-cycloalkyl,
 -Alk-C(=O)NRR',
 -Alk-(O)_m-Ar,
 -Alk-O-Alk, or
 -Alk-O-Alk-Ar;

R₂ is -OH, -OAlk, -NR₇R₈, -OAr, or -O-cycloalkyl;

R₇ is H or -Alk;

R₈ is

-H;

-Alk' or -cycloalkyl,

which Alk' or cycloalkyl is optionally substituted by one or more of -OAlk, -CN, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_m-cycloalkyl, -COOH or -NO₂;

-Ar',

which Ar' is optionally substituted by one or more of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH -NRR', -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_m-cycloalkyl or NO₂;

R₃, R₄, R₅ and R₆, which may be identical or different, are each independently, H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' or -NO₂;

Alk, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, or -NO₂;

Ar, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -NO₂, -S(O)_n-Ar or -S(O)_nAlk;

R and R' are, independently, H or Alk;

m is 0 or 1;

n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;
Ar and Ar' are, each independently, an aryl radical; and
Hal is a halogen radical;

or a pharmaceutically acceptable salt thereof.

33. (New) A method according to claim 22, wherein

X is S;

R1 is

-Alk-COOH,

-Alk-C(=O)-(O)_m-Ar,

-Alk-C(=O)-(O)_m-Alk,

-Alk-C(=O)-(O)_m-cycloalkyl,

-Alk-C(=O)NRR',

-Alk-(O)_m-Ar,

-Alk-O-Alk, or

-Alk-O-Alk-Ar;

R2 is -OH, -OAlk, -NR⁷R⁸, -OAr, or -O-cycloalkyl;

R⁷ is H or -Alk;

R⁸ is

-H;

-Alk' or -cycloalkyl,

which Alk' or cycloalkyl is optionally substituted by one or more of -OAlk, -CN, -OH, -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_m-cycloalkyl, -COOH or -NO₂;
-Ar',

which Ar' is optionally substituted by one or more of Hal, -OAlk, -OH, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH -NRR', -C(=O)-(O)_mAlk, -C(=O)-(O)_mAr, -C(=O)-(O)_m-cycloalkyl or NO₂;

R³, R⁴, R⁵ and R⁶, which may be identical or different, are each independently, H, -Hal, -OH, -Alk, -OAlk, -CN, -CF₃, -NRR' or -NO₂;

Alk, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -COOH, -NRR', -C(=O)-(O)_mAlk, or -NO₂;

Ar, each of which may be identical or different, is optionally and independently substituted by one or more of -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, -CF₃, -AlkAr, -COOH, -C(=O)-(O)_mAlk, -Alk-C(=O)-(O)_mAlk, -NRR', -NO₂, -S(O)_n-Ar or -S(O)_nAlk;

R and R' are, each independently, H or Alk;

m is 0 or 1;

n is 0, 1 or 2;

Alk and Alk' are, each independently, an alkyl radical;

Ar and Ar' are, each independently, an aryl radical; and

Hal is a halogen radical;

or a pharmaceutically acceptable salt thereof.